HB8667, the “MISSION Rx Act,” would tie certain Department of Defense, Department of Veterans Affairs, and federal procurement drug prices to the Medicare drug price negotiation framework. The bill amends Title 10 and Title 38 of the U.S. Code so that, for drugs selected under the Social Security Act’s Drug Price Negotiation Program, TRICARE cost-sharing for eligible beneficiaries and VA copayments for veterans could not exceed the amount paid by Medicare beneficiaries for the same drug in that year.
The bill also limits the price the Department of Veterans Affairs and certain other federal agencies may agree to pay for selected drugs procured under VA master agreements. For any selected drug covered by the Medicare negotiation program, manufacturers entering into or renewing a master agreement would be barred from setting a maximum price above the Medicare maximum fair price for the duration of that agreement. The bill includes conforming amendments and a fallback rule requiring master agreements to be modified if the Medicare negotiation program ends.
In practical terms, the bill would affect TRICARE beneficiaries, veterans using VA pharmacy benefits, drug manufacturers contracting with the federal government, and federal agencies that purchase prescription drugs. It would incorporate Medicare’s negotiated drug pricing definitions into veterans’ and federal procurement statutes, thereby extending the reach of the Medicare drug price negotiation system beyond Medicare itself.
The available legislative context shows no recorded votes or committee hearing transcript, so there is no documented floor or committee debate to gauge broader sentiment. Based on the bill’s sponsors and structure, the measure appears aimed at lowering prescription drug costs for servicemembers and veterans and aligning federal purchasing power with Medicare’s negotiated prices. The absence of recorded opposition in the provided materials means specific points of contention are not documented here, though the main policy issue is the extent to which Medicare-negotiated prices should be applied to military and veterans’ drug benefits and federal procurement contracts.
Impact
The bill would amend 10 U.S.C. § 1074g, 38 U.S.C. § 1722A, and 38 U.S.C. § 8126, and it would make conforming changes to the Social Security Act’s drug price negotiation provisions. It would cap TRICARE and VA beneficiary cost-sharing for selected drugs at the Medicare negotiated amount and would require federal drug procurement agreements to reflect the Medicare maximum fair price for those drugs. If enacted, it would effectively import Medicare negotiation benchmarks into military health care, veterans’ pharmacy benefits, and certain federal purchasing arrangements.
Sentiment
The bill’s apparent purpose is cost reduction for servicemembers, veterans, and federal purchasers, and the sponsor list suggests a bipartisan or cross-party coalition in support of that goal. However, because there are no committee transcripts or votes in the provided record, the formal legislative sentiment cannot be measured from debate or roll call data. The available text indicates a generally supportive policy posture toward using negotiated drug prices to reduce out-of-pocket costs and federal spending.
Contention
No specific objections are documented in the provided materials, but the likely areas of contention are the bill’s extension of Medicare-negotiated prices into TRICARE, VA copayments, and federal procurement contracts, and the effect that could have on manufacturers’ pricing flexibility and federal purchasing rules. Another possible issue is administrative complexity, since the bill ties multiple statutes to the operation of the Medicare Drug Price Negotiation Program and requires automatic adjustments if that program changes or terminates. Because no hearing record is included, it is not possible to attribute these concerns to any named member or stakeholder from the supplied context.